Prelude Therapeutics Incorporated : January 2023 Corporate Presentation

Corporate Presentation

January 2023

Forward Looking Statements

This presentation contains "forward-looking" statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: our plans to develop and commercialize small molecule therapies, our expectations about timing and ability to commence, enroll or complete clinical studies, present data and clinical results or updates, and to obtain regulatory approvals for PRT543, PRT811, PRT1419, PRT2527, PRT3645, PRT3789 and other candidates in development, the ability of our product candidates to treat various cancers, the ability to discover additional suitable candidates for regulatory approval, the potential impact of the COVID-19 pandemic, and the sufficiency of our cash and cash equivalents to fund our operations.

Any statements contained herein or provided orally that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by such terminology as ''believe,'' ''may,'' ''will,'' ''potentially,'' ''estimate,'' ''continue,'' ''anticipate,'' ''intend,'' ''could,'' ''would,'' ''project,'' ''plan,'' ''expect'' and similar expressions that convey uncertainty of future events or outcomes, although not all forward-looking statements contain these words. Statements, including forward-looking statements, speak only to the date they are provided (unless an earlier date is indicated).

Certain data in this presentation are based on cross-study comparisons and are not based on any head-to-head clinical trials. Cross-study comparisons are inherently limited and may suggest misleading similarities or differences. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

These forward-looking statements are based on the beliefs of our management as well as assumptions made by and information currently available to us. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. If such assumptions do not fully materialize or prove incorrect, the events or circumstances referred to in the forward-looking statements may not occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in our expectations, except as required by law. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Additional risks and uncertainties that could affect our business are included under the caption "Risk Factors" in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission for the three months ended September 30, 2022 and in our upcoming Annual Report on Form 10-K for the year ended December 31, 2022.

2

Prelude Therapeutics: Delivering Precision Medicines to Patients

Powerful R&D Engine

Diversified Pipeline		Large Commercial
	Opportunities

Exceptional Team		Well Capitalized

3

Prelude Discovery and Development Engine: Positioned to Succeed

R&D ENGINE

Internal Clinical

Discovery Development

Engine Expertise

APPROACH

Target

Mechanisms that drive

meaningful benefit in patients

with cancer

Discover

Optimized molecules that overcome the limitations of current treatments

Translate

Science into meaningful treatments for patients

DIFFERENTIATED

PIPELINE

CDK9MCL1

inhibitor inhibitor

SMARCA2 CDK4/6

degrader inhibitor

4

Experienced Management Team: Proven Track Records

Jane Huang M.D.	Laurent Chardonnet
President and Chief	Chief Financial Officer
Medical Officer

Kris Vaddi, PhD

Founder &

Chief Executive Officer

Andrew Combs, PhD

Executive Vice President

and Head of Chemistry

Peggy Scherle, PhD

Chief Scientific Officer

Board of Directors

Paul Friedman, MD

CEO

Former CEO

Mardi Dier

Former CFO

Former CFO,

CBO

Victor Sandor, MD

Former CMO

David Bonita, MD

General Partner

Julian C. Baker

Managing Member

Baker Brothers Investments

Kris Vaddi, PhD

Founder &

Chief Executive Officer

Martin Babler

Former CEO

5